An overview of allergic and bacterial conjunctivitis

N Schellack, N Shirindza, T Mokoena

School of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University, South Africa

Corresponding author, email: natalie.schellack@smu.ac.za

Conjunctivitis affects many people across the globe, significantly disturbing the quality of life of the people who are affected. Conjunctivitis can be divided into infectious and noninfectious causes. Viruses and bacteria are the most common infectious causes. Some of the most commonly diagnosed allergic diseases include atopic dermatitis, rhinitis, allergic conjunctivitis and sinusitis. Other conditions, such as eosinophilic oesophagitis, the prevalence of which is on the rise, are being diagnosed across all continents, except for Africa.

Allergic conjunctivitis is an allergic disease characterised by inflammation of the conjunctiva caused by airborne allergens; it presents as itching, excessive lacrimation, discharge and pink eye. Usually it is associated with other allergic conditions such as allergic rhinitis and bronchial asthma. Allergic conjunctivitis is further divided into acute, seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC). Bacterial conjunctivitis, caused by bacterial and viral pathogens, may include three major categories: hyperacute bacterial conjunctivitis, acute conjunctivitis and chronic conjunctivitis. The diagnosis is primarily clinical.

This article provides an overview of these conditions and their current management options.

Keywords: allergic disease, antihistamine, anaphylaxis, atopy, atopic march, rhinitis, sinusitis

Introduction

Allergic diseases are complex diseases caused by a combination of genetic and environmental factors. Allergic diseases are on the increase, affecting approximately 30% to 40% of the world’s population. They decrease quality of life and may have an immense influence on personal, social, and economic costs.  

An allergic response is a hypersensitivity reaction mediated by the adaptive immune system. The presence of a trigger, such as an allergen or antigen, induces a humoral immunological response, which in turn initiates a complex immunological reaction. This dysregulation in the immune function elevates the plasma levels of immunoglobulin E (IgE). The release of IgE is followed by binding to the allergen or antigen, which in turn stimulates the mast cells to degranulate and release several pro-inflammatory substances that include histamine, chemokines and numerous cytokines.

There are many different factors that come into play when searching for the causative agent of allergy. Environmental influences that occur in pregnancy and early childhood can alter the physiological, immune, structural and behavioural development and thus transform response patterns that influence susceptibility to future diseases. Genetics also play a vital role in the susceptibility of an individual to an allergic disease. The most common allergic conditions around the world include atopic dermatitis, rhinitis, asthma, rhinosinusitis, allergic conjunctivitis and, most recently, allergic oesophagitis. Allergic conjunctivitis is primarily a condition that affects young adults, with the average age of onset being 20 years. The symptoms, however, decrease with age.

Bacterial and viral pathogens can cause infective conjunctivitis which can further be differentiated into acute infective conjunctivitis and chronic conjunctivitis. Acute infective conjunctivitis is defined as inflammation of the conjunctiva due to infection that does not last longer than three weeks, whereas chronic conjunctivitis is defined as inflammation of the conjunctiva that lasts longer than three weeks.

The atopic march

Atopy refers to the increased sensitivity of IgE to a specific antigen, which, in turn, results in a hypersensitive response upon exposure to the specific allergen in question. Atopic march is a term that refers to the development of various atopic diseases that may develop during childhood. The atopic march may also refer to how the sequence of clinical symptoms and atopic disease manifest during childhood growth and development. The initial development of atopy has been linked to various predisposing risk factors. These include a genetic predisposition, decreased exposure to infections and endotoxins, postnatal antibiotic use, obesity, tobacco smoke, air pollutants, exposure to allergens, maternal weight gain or obesity, gestational use of antibiotics and maternal stress.

Pathophysiology of atopy

There is vast evidence that shows that T-lymphocytes play a major role in allergic diseases. The T-helper cell type 1 (Th1)/T-helper cell type 2 (Th2) paradigm has been extensively studied and seems to be the major pathological pathway in allergic diseases. The paradigm explains the relationship between the Th1 and Th2 subsets of the T lymphocyte. Th1 and Th2 subsets tend to differentiate from CD4+ naïve T lymphocytes. This
An overview of allergic and bacterial conjunctivitis

The role of histamine in allergy

Histamine is an endogenous substance synthesised from histidine. It has the ability to elicit autacoid effects within peripheral tissues and also acts as a neurotransmitter within the central nervous system (CNS). The role of histamine in the inflammatory process remains significant in understanding the pathophysiology thereof. The release of histamine in peripheral tissue areas is mediated by mast cell degranulation. This degranulation can be triggered in various ways. In allergic diseases, an interaction between IgE (immunoglobulin E) antibodies and suitable IgE antigens (i.e. the formation of antigen–antibody complexes) that causes allergic reactions (localised histamine release) or anaphylaxis (systemic histamine release), seems to be the major trigger.

There are currently four identified histaminergic receptor subtypes (i.e. the H1 to H4 receptors). The H1-receptor is the main active subtype in mediating acute allergic reactions. There are different effects that may be induced by H1-receptor stimulation. Some of these effects lead to allergic conditions, which include allergic rhinitis and conjunctivitis, urticaria, pruritus and angioneurotic oedema.

Stimulation of these receptors is also responsible for the vasodilatation and the increased vascular (capillary) permeability that accompany allergic reactions and inflammation. Erythema and oedema, including potentially fatal glottis oedema. Understanding histamine regulation assists in the type of treatment to be initiated in various allergic reactions. For instance, histamine is released systemically in anaphylaxis but the use of an antihistamine alone is not effective in treating anaphylaxis.
Genetic predisposition

Allergies tend to be familial, with patients who suffer from an allergy tending to have an increased risk of having children with some form of atopy. There is vast evidence that shows that T lymphocytes play a major role in allergic diseases. Several studies have examined the role of genetics in allergic diseases. Some studies have had mitochondrial RNA (miRNA) as the main focus of such investigations. The earlier studies have shown that several types of miRNA augment the sensitivity of T cells to peptide antigens. Evidence suggests that inhibition of miR-181a expression in immature T cells significantly decreases sensitivity to antigens and enhances the impairment of T-cell selection. T-cell apoptosis is crucial in regulating both the length and strength of T-cell responses. MiR-21 has also been extensively studied, showing significant upregulation during T-cell activation and playing a role in the suppression of apoptosis in activated T cells. It is therefore essential to understand the role of various miRNA in T-cell regulation as the development of polarised T cells is central to the pathogenesis of allergic inflammation because allergic inflammation is predominately a Th2 response.

Allergen exposure

Exposure to an allergen in individuals with an atopic disease increases the risk of developing a hypersensitivity reaction, regardless of the level of antigen exposure. The evidence showing that immune sensitisation is not dependent on the level of allergen exposure gives credibility to a belief that the existence of atopic disease is hereditary. On the contrary, low levels of allergen exposure are not sufficient to produce a response, while high levels of allergen exposure induce tolerance toward that allergen, i.e. desensitisising it.

Infections and endotoxin exposure

The hygiene hypothesis is applied in most atopic diseases. It predicts that the prevalence of atopic diseases is decreased when a child is exposed to more infectious agents. It is estimated that the exposure to animals, viruses, bacteria and various endotoxins makes children less likely to develop an atopic disease. The hygiene hypothesis emerges from the understanding that bacterial, viral and endotoxin factors trigger an immune response of Th1 lymphocytes. Th1 lymphocytes increase the production of IgG antibodies. Th1 (through IgG) indirectly suppresses the activity of Th2 which mediates the release of various cytokines including IgE. These Th2 cytokines are common culprits in the development of allergic diseases.

Intestinal flora

The presence of microbes in the walls of the intestinal tract helps to regulate an immune response. Exposure early in life to microbial flora within the gastrointestinal tract, allows for a change in the Th1:Th2 cytokine balance, favouring a Th1 cell response. A shift in the microbial balance initiates a change in immune response. The evidence then suggests that exposure to high dosages of antibiotics in early neonates may alter the composition of intestinal flora, leaning towards an immune response with elevated levels of Th2. The elevated Th2 leads to increased IgE production and therefore the likelihood of developing an atopic disease.

Conjunctivitis

Allergic conjunctivitis

Allergic conjunctivitis is an inflammatory response of the conjunctivae to allergens such as pollens, environmental antigens (e.g. dust), and animal dander. Hyperaemic conjunctivitis is a common type of conjunctivitis; most patients show symptoms of ocular itching, lacrimation, hyperaemia, eye discharge, etc. Severe symptoms cause eyelid swelling. A number of conditions may present with conjunctivitis (red eye), but it would be best to try and differentiate allergic conjunctivitis from other eye conditions. Knowledge of eye conditions, how they present and their prevalence is important.

Types of allergic conjunctivitis

Allergic conjunctivitis can be differentiated into three types: acute allergic conjunctivitis, seasonal allergic conjunctivitis (SAC), and perennial allergic conjunctivitis (PAC). The differences between these three types are demonstrated in Table I below, and before a likely diagnosis is made, the following should be considered – the causative agent involved, types of discharge, ocular symptoms and lastly, other accompanying symptoms (Table II).

Bacterial conjunctivitis

Bacterial conjunctivitis has a seemingly higher incidence in paediatrics than in adult patients. Conjunctivitis is often a self-limiting illness and antibiotics should be used only in cases where bacterial conjunctivitis has been confirmed. It is vital that the correct diagnosis is made early so as to identify the cause and start the correct treatment promptly. Furthermore, it is essential to rule out more serious causes that could be classified as a

<table>
<thead>
<tr>
<th>Type of allergic conjunctivitis</th>
<th>Onset</th>
<th>Causes</th>
<th>Allergens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute allergic conjunctivitis</td>
<td>Sudden onset, develops rapidly (within 30 mins) and resolves immediately in the absence of the allergen (within 24 hours)</td>
<td>Environmental exposure</td>
<td></td>
</tr>
<tr>
<td>Seasonal allergic conjunctivitis (SAC)</td>
<td>Progressive onset and occurs gradually over days to weeks</td>
<td>Specific allergen</td>
<td>Tree pollen in spring Grass pollen in summer Wood pollen in late summer or autumn</td>
</tr>
<tr>
<td>Perennial allergic conjunctivitis (PAC)</td>
<td>It is mild and chronic that can either increase or decrease in severity</td>
<td>Year round environmental exposure</td>
<td>Dust mites Animal dander Moulds</td>
</tr>
</tbody>
</table>
An overview of allergic and bacterial conjunctivitis

Emerging therapies for allergic conjunctivitis

Topical combination antihistamine/mast cell stabilisers e.g. olopatadine provide an additional, immediate relief benefit as well as long-term relief from the mast cell stabilisation. This combination also has the additional advantage of once-daily dosing. There is a recognised need for medications that demonstrate rapid onset and a prolonged duration of action. Twenty-four-hour dosing provides maintenance therapy during symptomatic periods without any exposure to preservatives because of fewer instillations. It also promotes compliance. A higher concentration of the olopatadine (antihistamine/mast cell stabiliser) is the newest combination therapy. Olopatadine, when compared to sodium cromoglycate, showed that the more expensive olopatadine had fewer patient return visits.

Management of allergic conjunctivitis

Allergic diseases can be strategically managed both non-pharmacologically and pharmacologically. The use of pharmacological preparations is usually preferred when non-pharmacological methods prove ineffective or insufficient in alleviating the allergic symptoms. Different pharmaceutical preparations (systemic, intranasal, topical etc.) are used depending on the symptoms and type of allergic disease.

Topical therapy consists either of combination drugs such as an antihistamine and a vasoconstrictor, or antihistamines with mast cell stabilising properties. The former is found over-the-counter; the vasoconstrictor targets the ocular redness and the antihistamine targets the allergic symptoms. An example is the tetryzoline/antazoline combination that may, however, cause increased redness for several days after use. The latter, that is the antihistamine with mast cell stabilising properties, has a dual mechanism of action; it blocks histamine receptors and also
an overview of allergic and bacterial conjunctivitis

stabilises mast cells, inhibiting their degranulation which in turn limits the release of histamine, tryptase and prostaglandin D2. They also have an effect on leukocyte activity. These drugs are dosed twice daily.

**Local vs systemic antihistamines in the treatment of allergic conjunctivitis**

Based on randomised trials, topical medications are more effective compared to oral therapies when used for ocular conditions.5 The systemic use of antihistamine only relieves ocular allergic symptoms partially and patients may also experience systemic adverse effects such as drowsiness and dry mouth.26,27 Therefore topical administration, especially of a combination (antihistamine/decongestant), is more effective for ocular allergic symptoms. However, in the situation where oral therapy is used, the second-generation antihistamines are preferred as they cause less sedation because of their reduced ability to cross the blood brain barrier.26,27

**Local decongestants**

Local decongestants are mainly sympathomimetic drugs that stimulate α1-adrenergic receptors producing vasoconstriction. This in turn decreases mucosal oedema and local vasoconstriction.26 Examples of the most commonly used drugs include xylometazoline, phenylephrine and oxymetazoline.26 Local decongestants are usually indicated to reduce acute symptoms as prolonged use can produce undesirable effects to the user.23,26 After persistent use (usually more than five days), rebound rhinitis and conjunctivitis medicamentosa start to appear. Oxytnetazoline and xylometazoline have a long-acting effect on the α1-receptor, whereas phenylephrine has a shorter duration of action, lasting up to approximately four hours.21 The mechanisms of action of the local decongestants illustrated in Figure 3. It involves targeting the vasodilatation of the mucosal oedema (1) that causes nasal congestion the molecules of a suitable nasal decongestant (2) bind to, and stimulate adrenergic alpha 1-receptors (3) resulting in vasoconstriction and therefore alleviates the mucosal oedema, thus increasing the diameter of the nasal lumen.

**Systemic decongestants**

These agents stimulate α1-receptors producing vasoconstriction, reducing oedema, redness and itching. Their preparations usually contain an antihistamine. It is important to note that combination therapy of a systemic decongestant and an older-type H1-antihistamine can produce drowsiness and a lack of motor coordination. Systemic decongestants available in South Africa include pseudoephedrine, phenylpropanolamine and phenylephrine. The use of phenylpropanolamine has produced sub-arachnoid bleeding with a haemorrhagic stroke in women using it as an appetite suppressant. The total daily dosage of phenylpropanolamine should not exceed a 100 mg.25,26

**Corticosteroids**

Glucocorticosteroids can be used for various allergic conditions such as asthma, allergic rhinitis and minimal use in allergic conjunctivitis. They exert their pharmacological action by modifying protein synthesis through regulating transcription, and indirectly by modifying the activity or half-life of transcription factors and mRNA. The currently available intranasal corticosteroids include: beclometasone, budesonide, fluticasone, mometasone, triamcinolone and ciclesonide. The newer agents, namely mometasone, fluticasone, and ciclesonide, are also administered intranasally and result in minimal systemic effects.27,28 The most common local side-effects experienced with the intranasal corticosteroids include dryness, stinging, burning, and epistaxis. Chronic use of topical corticosteroids may lead to atrophy of the nasal mucosa. It is therefore advisable to use these agents for the shortest time possible to prevent unpleasant adverse effects associated with long-term use.28 Systemic corticosteroids such as hydrocortisone and prednisone can be used in chronic dermatitis to reduce frequency of allergic flares.28

**The H1-antihistamines**

H1-antihistamines based on pharmacological classification, are grouped into different generations. This system of classification is based on their target receptors as well as side-effect profile.21 The H1-antihistamines are classified into first generation (older, sedating multi-potent blockers) and second generation (non-sedating, newer) antihistamines. First-generation antihistamines include promethazine, chlorpheniramine, dexamethasone and cyclosporin whilst the second-generation antihistamines include cetirizine (and levocetirizine), loratadine, ebastine, fexofenadine and mizolastine. The most significant difference (refer to Table III) between the two classes is that first-generation H1-antihistamines have the ability to cross the blood-brain barrier and the second-generation non-sedating H1-antihistamines have very limited ability, if none at all, to cross the blood-brain barrier. It is also important to note that two generations of systemic (oral and/or parenteral) agents, topical (including intranasal and ophthalmic) H1-antihistamines are available as well.29,30

---

**Figure 3:** The mechanisms of action of the local decongestants

---

First-generation H<sub>1</sub>-antihistamines

These older H<sub>1</sub>-receptor blockers have been shown to have sedative and multi-potent receptor blocking abilities. Their ability to cross the blood-brain barrier distinguishes them from the newer generation H<sub>1</sub>-antihistamines. The chemical structure of the first-generation antihistamines permits them to have a certain degree of non-selectivity, exerting antagonistic effects of an antimuscarinic or anticholinergic, antihistaminergic, α<sub>1</sub>-adrenergic blocking, anti-serotonergic and local anaesthetic nature. Because of their wide range of receptor blocking, the first-generation H<sub>1</sub>-antihistamines have a variety of indications and uses, which range from allergies and rhinoconjunctivitis, to nausea and vomiting, motion sickness and insomnia. Their effects on multiple receptors, on the other hand, also have undesirable effects (refer to Table IV) and are not recommended for use in patients who suffer from glaucoma, benign prostatic hypertrophy.

Table III: The differences between first- and second-generation H<sub>1</sub>-antihistamines

<table>
<thead>
<tr>
<th>Drug examples</th>
<th>Older, first-generation H&lt;sub&gt;1&lt;/sub&gt;-antihistamines</th>
<th>Newer, second-generation H&lt;sub&gt;1&lt;/sub&gt;-antihistamines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promethazine</td>
<td>Chlorpheniramine</td>
<td>Cetirizine and levocetirizine</td>
</tr>
<tr>
<td>Chlorpheniramine</td>
<td>Dexchlorpheniramine</td>
<td>Loratadine</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>Cyclizine</td>
<td>Ebastine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fexofenadine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mizolastine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rupatadine</td>
</tr>
</tbody>
</table>

Table IV: The adverse effects of first-generation H<sub>1</sub>-antihistamines, as reflected by receptor activity

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Antagonistic interaction</th>
<th>Side-effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&lt;sub&gt;1&lt;/sub&gt;</td>
<td>A reduction in central nervous system neurotransmission, sedation, reduced cognitive and neuro-psychomotor performance, and an increased appetite</td>
<td></td>
</tr>
<tr>
<td>Muscarinic receptor</td>
<td>Xerostomia, urinary retention and sinusoidal tachycardia</td>
<td></td>
</tr>
<tr>
<td>α-adrenergic receptor</td>
<td>QTc-interval prolongation and ventricular arrhythmias</td>
<td></td>
</tr>
<tr>
<td>Serotonergic receptor</td>
<td>An increased appetite</td>
<td></td>
</tr>
<tr>
<td>I&lt;sub&gt;Kr&lt;/sub&gt; and other cardiac channels receptors</td>
<td>QTc-interval prolongation and ventricular arrhythmias</td>
<td></td>
</tr>
</tbody>
</table>

Side-effects

Potentially cause side-effects, such as:
- Sedation
- Drowsiness and dizziness
- Hyperactivity (meta-reaction)
- Insomnia
- Convulsions
- Impaired driving performance
- Fatigue and lassitude (well documented)

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Case reports of toxicity are regularly published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overdose</td>
<td>A lethal dosage has been identified in infants and young children</td>
</tr>
</tbody>
</table>

Minor side-effects include:
- Nausea
- Light headedness
- Drowsiness
- Headaches
- Agitation and a dry mouth

Do not cause side-effects (sedation, fatigue, hyperactivity and convulsions) in the absence of drug interactions

Do not cause fatalities in overdose

Do not cause side-effects (sedation, fatigue, hyperactivity and convulsions) in the absence of drug interactions
hyperplasia and in cardiac patients (i.e. ischaemic heart disease, myocardial infarction and congestive heart failure).29-33

The following drugs in this group are of note:

- The options include hydroxyzine, promethazine and diphenhydramine. These drugs are used in the management of insomnia but there are more suitable agents that may be used.

- Cyclizine (syn. meclizine), diphenhydramine, hydroxyzine or promethazine, are examples of antiemetic agents. First-generation H₁-antihistamines may be very useful in the management of postoperative nausea and vomiting, as well as vertigo.

- Chlorpheniramine is better suited for use in allergic reactions due to its relatively lower sedation levels than the other first-generation antihistamines.

It should be noted that these “older” drugs have never been optimally investigated and profiled from a clinical pharmacology perspective.

Second-generation H₁-antihistamines

Second-generation H₁-antihistamines are relatively newer antihistamines that do not possess the ability to cross the blood-brain barrier. They also have no antiemetic, anticholinergic and central nervous system effects, unlike the first-generation antihistamines. Drugs like fexofenadine are actively transported into the lumen of the gut, kidney and brain by p-glycoproteins, which restrict their ability to accumulate and cause unwanted side-effects. However, agents such as rifampicin, which induce p-glycoprotein, may increase the clearance of fexofenadine and reduce their efficacy.34 Second-generation H₁-antihistamines are mostly dosed once daily with minimal risk of developing tolerance. The long-term safety of the second-generation H₁-antihistamines (cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine) has been documented in randomised controlled trials lasting 6–18 months in adults, and in children as young as 1–2 years old.35

Ophthalmic (eyedrop) preparations include levocabastine, epinastine, olopatadine and ketotifen (Olopatadine and ketotifen also act as mast cell stabilisers). Levocabastine, in addition to azelastine, is also available as a nasal spray for use in patients who suffer from allergic rhinitis.36

Rupatadine fumarate is a newly launched, second-generation, long-acting histamine antagonist (H₁-receptor antagonist) and platelet-activating factor receptor inhibitor. Rupatadine fumarate is approved for the treatment of allergic rhinitis and chronic urticaria in adults and children aged 12 years and older. It inhibits the degranulation of mast cells and the subsequent release of cytokines, more specifically of tissue necrotising factor which is available in mast cells and monocytes.37

The leukotriene-receptor antagonists

Examples of leukotriene receptor antagonists include zafirlukast and montelukast. They are competitive antagonists of the cysteinyl leukotriene receptor-1 (cysLT-1). They have the advantage of oral administration. Montelukast is also available as a sprinkle and in a chewable tablet form for the convenient use in paediatrics. Montelukast presents an additional option in the management of seasonal allergic rhinitis in children with asthma.12,23

Mast cell stabilisers

They act by stabilising mast cells thus preventing the release of histamine. The maximum effect is reached after 5–14 days administration and they are dosed more frequently than topical antihistamines i.e. four times daily. Therefore, they are not used in the treatment of acute allergic conjunctivitis and they are reserved for the treatment of SAC in patients that cannot tolerate other therapy.6 Lodoxamide is a mast cell stabiliser indicated for atopic conjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis and allergic conjunctivitis.

Management of bacterial conjunctivitis

Acute bacterial conjunctivitis is often a self-limiting condition however when specifically indicated, patients treated early (within day 2–5) with topical antibiotics may have improved clinical outcomes.6

The majority of uncomplicated acute bacterial conjunctivitis cases are treated by clinicians with empirical topical antibiotics at diagnosis. There are several other treatment options available that include:6

- delaying treatment for five days and then beginning treatment if no sign of improvement is observed, and
- treating patients who have clinical features associated with a bacterial cause.
- Studies comparing the effectiveness of different antibiotics recommended for use in suspected bacterial conjunctivitis have shown similar levels of effectiveness. Therefore, it is important to consider local bacterial resistance and cost-effectiveness of the antibiotics being prescribed. All antibiotic courses should be taken for 7–10 days. Compliance with the length of time the antibiotics are prescribed for is particularly important to help prevent the development of resistance.

The first-line treatment in mild to moderate bacterial conjunctivitis is tobramycin. In moderate to severe infections, or antibiotic-resistant infections, and in immunocompromised patients, fluoroquinolones are recommended.6 These include ofloxacin, ciprofloxacin, moxifloxacin and gatifloxacin. Chlamydial conjunctivitis requires oral antibiotics together with a topical antibiotic to treat the infection.6 The oral antibiotic options include azithromycin, doxycycline, or erythromycin. In addition, patients should be advised to take several precautions to help prevent spread of the infection. Patients should wash their hands regularly and thoroughly, especially after touching any infected secretions. Furthermore, patients should avoid sharing towels, pillows, or utensils.6

Conclusion

The incidence of conjunctivitis seems to be on a constant rise and affects a large percentage of the population. Allergic
and bacterial conjunctivitis can decrease quality of life and productivity and can be exacerbated by the presence of comorbid conditions such as rhinitis. A stepwise approach to treatment should be taken. The topical antihistamines/mast-cell stabiliser formulations are the first treatment approach because of their ability to relieve symptoms rapidly, and because they are suitable and well-tolerated for long-term use. However, the development of newer drugs with prolonged duration of action and specificity provides more options to the prescriber.

References
1. Tamari M, ShotaTanaka, Hirota T. Genome-wide association studies of allergic and specificity provides more options to the prescriber.